Eisai: Looking To Upside Targets Following Leqembi Full Approval (OTCPK:ESALF) - Seeking Alpha
seekingalpha.comSubmitted by seekingalpha1903 in business
FDA approved Eisai's Leqembi label last week, developed with Biogen, for treatment of adult patients with Alzheimer's Disease. Find out why ESALF stock is a Buy.